Bolt Biotherapeutics (NASDAQ: BOLT) director receives 5,000-share stock option grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Bolt Biotherapeutics director Jakob Dupont received a stock option grant covering 5,000 shares of common stock. The option has an exercise price of $4.43 per share and expires on June 9, 2036. It vests on the earlier of June 9, 2027 or the day before the next annual stockholder meeting, with full vesting upon a change in control, assuming continuous service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Dupont Jakob

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 5,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 5,000 shares Exercise price: $4.43 per share Expiration date: June 9, 2036 +2 more

5 metrics

Option grant size 5,000 shares Stock Option (Right to Buy) granted to director Jakob Dupont

Exercise price $4.43 per share Strike price of stock option grant

Expiration date June 9, 2036 Option term end date for the grant

Shares underlying option 5,000 shares Underlying common stock tied to the option

Vesting outside change in control Earlier of June 9, 2027 or pre-annual meeting Time-based vesting condition with continuous service

Key Terms

Stock Option (Right to Buy), exercise price, change in control, continuous service, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price": "4.4300""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

change in control financial

"the option will vest in full upon a change in control of the Issuer"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

continuous service financial

"subject to the Reporting Person's continuous service through such date"

annual meeting of stockholders financial

"the day immediately prior to the next annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/11/2026 - 04:12 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dupont Jakob

(Last)

(First)

(Middle)

C/O BOLT BIOTHERAPEUTICS, INC.

900 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY

CALIFORNIA

94063

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bolt Biotherapeutics, Inc. [ BOLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$4.43	06/10/2026		A		5,000		⁽¹⁾	06/09/2036	Common Stock	5,000	$0	5,000	D

Explanation of Responses:

1. The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.

	/s/ William P. Quinn, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Bolt Biotherapeutics (BOLT) report for Jakob Dupont?

Bolt Biotherapeutics reported that director Jakob Dupont received a stock option grant for 5,000 shares. The option allows him to buy common stock at a fixed price, functioning as equity-based compensation rather than a market purchase or sale.

What are the key terms of Jakob Dupont’s Bolt Biotherapeutics stock option?

The stock option covers 5,000 shares of Bolt Biotherapeutics common stock at an exercise price of $4.43 per share. It expires on June 9, 2036, providing a long-dated incentive aligned with the company’s future performance and Dupont’s continued service.

How and when do Jakob Dupont’s Bolt Biotherapeutics options vest?

The options vest on the earlier of June 9, 2027 or the day immediately before the next annual stockholder meeting. Vesting is conditioned on Jakob Dupont’s continuous service with Bolt Biotherapeutics through that date, aligning compensation with ongoing board participation.

What happens to Jakob Dupont’s Bolt Biotherapeutics options if there is a change in control?

If Bolt Biotherapeutics undergoes a change in control, Jakob Dupont’s stock option will vest in full. This means all 5,000 option shares become exercisable, accelerating vesting in connection with a significant corporate transaction affecting company ownership.

Is Jakob Dupont’s Form 4 transaction a stock purchase or sale of BOLT shares?

The Form 4 reports a grant of stock options, not an open-market purchase or sale. Jakob Dupont acquired derivative rights to buy 5,000 Bolt Biotherapeutics shares at $4.43, subject to vesting, rather than trading existing common stock in the market.